Effect of osteoporosis therapy with RANKL inhibitor on coronary calcifications

Effect of osteoporosis therapy with RANKL inhibitor on coronary calcifications - Effect of osteoporosis therapy with RANKL inhibitor on coronary calcifications

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026938

Enrollment

Registered

2017-04-11

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary artery disease

Interventions

We performed cardiac computed tomography to evaluate CAC score. One year after administration of denosumab, we measured their CAC score and compared their scores with those of a control group of femal

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: The women patient who has both CAD and osteoporosis and agree to participate in this study

Exclusion criteria

Exclusion criteria: 1. Patients who can not receive coronary CT 2. Patients with hypocalcemia 3. Patients with allergy to denosumab 4. Patients who will receive tooth extraction in a few days 5. Patients with the expected rest of their life less than 1 year 6. Patients with alcohol/drug dependence during the past 3 months 7. Patients without informed consent 8. Pregnant or possibly pregnant females 9. Patients with latex allergy 10. Patients judged inappropriate for this study by phisician 11. Patients without agreement

Design outcomes

Primary

Measure	Time frame
Progression of Coronary Artery Calcification(CAC) score	—

Countries

Japan

Contacts

Public ContactTakuya Ozawa

Niigata University Graduate School of Medical and Dental Sciences Department of Cardiovascular Biology and Medicine

takuya-o@med.niigata-u.ac.jp0252272185

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026